There are now three FDA-approved semaglutide pills, Rybelsus, Ozempic tablets and Wegovy tablets, and they are not all approved for the same use. Compounded oral semaglutide is not FDA-approved. Semaglutide at Telos Rx is available as a weekly injection, or as a compounded daily sublingual dose through the Oral GLP-1 programme, prescribed only after review by a licensed provider.
Most writing about the semaglutide pill is frozen in 2020, when Rybelsus was the only tablet and everything else came in a pen. Current FDA labels list three oral tablet products across two prescribing labels.
This page is the brand-and-format map. For the deeper route-versus-route analysis, see oral vs injectable semaglutide.
Six Semaglutide Products, Three of Them Tablets
Semaglutide is a GLP-1 receptor agonist made by Novo Nordisk. The confusion comes from one molecule carrying several brand names across two routes. Five of the six are FDA-approved. The sixth, compounded semaglutide, is not.
| Product | Form | Label strengths | FDA-approved for |
|---|---|---|---|
| Rybelsus | Oral tablet, daily | 3, 7, 14 mg | Type 2 diabetes, plus cardiovascular risk reduction in high-risk patients |
| Ozempic tablets | Oral tablet, daily | 1.5, 4, 9 mg | Same as Rybelsus, they share one label |
| Wegovy tablets | Oral tablet, daily | 1.5, 4, 9, 25 mg | Weight reduction in obesity or overweight with a related condition, plus cardiovascular risk reduction |
| Ozempic injection | Weekly injection | 0.25 to 2 mg | Type 2 diabetes |
| Wegovy injection | Weekly injection | 0.25 to 7.2 mg | Weight, cardiovascular risk, and noncirrhotic MASH with F2 to F3 fibrosis under accelerated approval |
| Compounded semaglutide | Varies | Varies | Not FDA-approved. Prepared by licensed US compounding pharmacies |
Rybelsus and Ozempic Tablets Are One Label, Two Strength Ranges
This is the detail most write-ups miss. Rybelsus and Ozempic tablets sit on a single shared prescribing label, so their indications are identical: glycemic control in adults with type 2 diabetes, and cardiovascular event risk reduction in adults with type 2 diabetes at high risk.
What differs is the strength ladder. Rybelsus is labelled at 3, 7 and 14 mg, Ozempic tablets at 1.5, 4 and 9 mg. Neither is approved for weight management. The naming tangle is unpicked further in is Ozempic semaglutide.
The Wegovy Pill Is the Weight-Management Tablet
The breakout search for a Wegovy pill now has a real answer. The Wegovy label covers both the injection and tablets at 1.5, 4, 9 and 25 mg, paired with a reduced calorie diet and increased physical activity.
The tablet is approved for reducing excess body weight in adults with obesity, or overweight plus at least one weight-related condition, and for reducing cardiovascular event risk in adults with established cardiovascular disease. Two limits matter. The MASH indication belongs to the injection only. And the label says using a semaglutide product alongside another GLP-1 receptor agonist is not recommended.
Why a Semaglutide Pill Needs an Absorption Helper
Semaglutide is a peptide. Swallowed alone, a peptide is broken down by stomach acid and enzymes before much reaches the bloodstream, which is why the molecule launched as an injection.
The tablets solve this with a co-formulated absorption enhancer called salcaprozate sodium, shortened to SNAC. The shared tablet label states that the tablets are co-formulated with SNAC, which facilitates the absorption of semaglutide after oral administration. SNAC raises local pH at the absorption site in the stomach so the peptide can cross into circulation. That one ingredient is why the rules below exist.
Not sure whether a tablet or an injection fits your situation? A licensed provider reviews your written intake and decides what, if anything, is appropriate.
See Semaglutide at Telos RxThe Empty-Stomach Conditions Are Part of the Label
Oral semaglutide carries administration conditions that injections do not. Across both tablet labels the wording is the same: one tablet once daily on an empty stomach in the morning with water, up to 4 ounces, and not with any other liquid. The tablet is swallowed whole, not split, crushed, chewed or dissolved, and at least 30 minutes should pass before food, other beverages or other oral medications.
The pharmacokinetic data explains the strictness. Absorption was higher after a longer post-dose fasting period, and the label reports no clinically significant difference between 50 mL and 120 mL of water. How any individual takes a prescribed medicine is directed by the prescribing provider and the dispensed label, not by an article.
How Oral Absorption Compares With Injection
The numbers are stark. The tablet label estimates absolute bioavailability at roughly 0.4 to 1 percent for Rybelsus 3, 7 and 14 mg, and roughly 1 to 2 percent for Ozempic tablets 1.5, 4 and 9 mg. Peak concentration arrives about an hour after an oral dose.
That is why milligram figures look so different across routes. A 25 mg daily tablet and a 2.4 mg weekly injection are not a mismatch, they are two ways of reaching comparable exposure. The Wegovy label reports that in patients without type 2 diabetes, average blood concentrations on 25 mg tablets daily were similar to 2.4 mg injection weekly, while in patients with type 2 diabetes the tablet concentrations were lower.
The consequences are practical. Daily dosing replaces weekly, timing of food and drink suddenly matters, and absorption varies more between people. Injection formats are compared in GLP-1 pens vs vials.
Compounded Oral and Sublingual Semaglutide
Some pharmacies prepare compounded semaglutide in oral or sublingual forms, marketed as drops, troches or dissolvable tablets.
Compounded semaglutide in any form is not FDA-approved. It has not been through the agency's own review of safety and effectiveness, and compounded oral and sublingual preparations have no published bioavailability data comparable to the branded tablet labels. A compounded oral preparation does not inherit the absorption profile of a SNAC-formulated tablet.
Compounded medications are prepared by licensed US compounding pharmacies under federal compounding regulations, against a prescription for an individual patient. They are not supplements and should never be sourced outside a licensed pharmacy, as covered in how to get GLP-1 therapy online safely.
Foundayo and Orforglipron Are a Different Molecule
Searches for a GLP-1 pill increasingly surface Foundayo. Foundayo is orforglipron, an Eli Lilly product approved in 2026. It is not semaglutide.
Orforglipron is a small-molecule GLP-1 receptor agonist rather than a peptide, so it needs no absorption enhancer. Its label indicates it with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity, or overweight with a weight-related condition. There is also no FDA-approved tirzepatide pill, which is covered in tirzepatide pills and oral tirzepatide.
What Telos Rx Prescribes, and How That Is Decided
Telos Rx offers compounded semaglutide as a weekly subcutaneous injection with clinician-directed titration, and as a compounded daily sublingual dose through its Oral GLP-1 programme, which covers oral semaglutide and oral tirzepatide under one intake. Neither is a SNAC-formulated tablet like Rybelsus, Ozempic tablets or Wegovy tablets, and the caveats in the compounded section above apply: compounded semaglutide is not FDA-approved in any form, and compounded sublingual preparations have no published bioavailability data comparable to the branded tablet labels.
Telos Rx is an online-first, asynchronous telehealth service. You complete a written intake covering health history and current medications, and a US-licensed clinician reviews it without a scheduled appointment and responds in writing. Approval is subject to evaluation by a licensed provider, and approval is not guaranteed. Semaglutide is not for use in pregnancy, and it carries a boxed warning for thyroid C-cell tumours plus a contraindication in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.
As of publication, the semaglutide product page lists pricing as low as $99 per month, flat as a clinician titrates the dose, with free 48-hour shipping if approved, FSA and HSA eligibility, and cancellation at any time. The Oral GLP-1 programme is priced separately, from $9 a day.
Keep Reading
- What Is Semaglutide? Complete Guide
- Oral vs Injectable Semaglutide: A Side-by-Side Comparison
- Semaglutide Dosage Schedule
- Semaglutide Cost and Price Guide
- Is Ozempic Semaglutide? Explained
Frequently Asked Questions
Is there a semaglutide pill?
Yes, three FDA-approved ones. Rybelsus at 3, 7 and 14 mg and Ozempic tablets at 1.5, 4 and 9 mg are approved for type 2 diabetes and cardiovascular risk reduction in high-risk patients. Wegovy tablets at 1.5, 4, 9 and 25 mg are approved for weight reduction and cardiovascular risk reduction. All are taken once daily.
Is there a Wegovy pill?
Yes. Wegovy tablets are an FDA-approved oral semaglutide, labelled at 1.5, 4, 9 and 25 mg. They are indicated with a reduced calorie diet and increased physical activity for reducing excess body weight in adults with obesity or overweight plus a weight-related condition, and for reducing cardiovascular event risk. The MASH indication belongs only to the injection.
Is Rybelsus the same as Ozempic?
Both contain semaglutide, and Rybelsus and Ozempic tablets share one prescribing label with identical indications. The difference is strength and form. Rybelsus is labelled at 3, 7 and 14 mg, Ozempic tablets at 1.5, 4 and 9 mg, and Ozempic injection is a weekly pen. Which is appropriate is a decision for the prescribing provider.
Why is the oral dose so much larger than the injection dose?
Because very little of a swallowed peptide reaches the bloodstream. The tablet label estimates absolute bioavailability at roughly 0.4 to 1 percent for Rybelsus and roughly 1 to 2 percent for Ozempic tablets. A larger milligram figure taken daily is how the oral route reaches exposure comparable to a much smaller weekly injection.
Is compounded oral or sublingual semaglutide FDA-approved?
No. Compounded semaglutide is not FDA-approved in any form, including oral drops, troches and sublingual preparations. It has not been through the agency's review of safety and effectiveness, and compounded oral forms have no published bioavailability data comparable to the branded tablets. It is prepared by licensed US compounding pharmacies against a prescription for an individual patient.
Is Foundayo a semaglutide pill?
No. Foundayo is orforglipron, a different molecule from Eli Lilly approved in 2026. It is a small-molecule GLP-1 receptor agonist rather than a peptide, so it needs no absorption enhancer. It is not semaglutide and not tirzepatide, and there is no FDA-approved tirzepatide pill.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Ready to find out whether semaglutide is a reasonable fit for you? Start with the semaglutide product page, then complete the written intake: start an online visit. A US-licensed clinician reviews every request, and approval is not guaranteed.